Magnolia Medical publishes report, entitled State of Hospitalized Patient Care in the U.S.

July 13, 2023

Report highlights perspectives and findings regarding hospitalization concerns, antimicrobial stewardship, infection concerns, sepsis, hospital-acquired infections (HAIs), and how the government is performing in terms of protecting the health of hospitalized Americans.

Key findings, include:

1. Costs: Given the current state of the economy, unsurprisingly, the most feared hospital risk for Americans is the financial cost of hospitalization. 55% of respondents indicating they were ‘Very’ or ‘Extremely’ fearful.
2. Antibiotics: An average of 3 out of 4 Americans agree that “Healthcare providers should be more cautious when prescribing antibiotics.”
3. Antibiotic Resistance: There is a significant knowledge gap regarding risks associated with “antimicrobial resistant bacteria” amongst previously and/or future hospitalized patients. Need for more government leadership between healthcare providers and patients given the dangers of AMR.
4. Infections from Resistant Organisms: 52% of respondents are ‘Very concerned’ or ‘Extremely concerned’ about the effects of infections caused by AMR on their current or future health. Agree that ”more education is needed for patients about antimicrobial resistant bacteria.”
5. Sepsis Concerns: Sepsis is not only the #1 cause of death, readmissions, and costs for U.S. hospitals, it is also the most feared infection (nearly half of respondents ‘Extremely’ or ‘Very’ fearful). Nearly one third of respondents either have had a loved one or have been personally diagnosed with sepsis. These respondents are more knowledgeable about AMR, HAIs, etc., most likely because they’ve been impacted by such a significant threat to their health and/or the health of a loved one.
6. Hospital-Acquired Infection Risk: Approximately 2 out of 5 respondents in non-medical related occupations were ‘Barely’ or ‘Not at all’ informed about the risk for hospital-acquired infections (HAIs). However, 81% agree that it is ‘Very’ or ‘Extremely’ important to be informed about HAI risk and infection control measures in the hospital if they were to be an admitted patient.
7. Government Protection of Patients: 46% of respondents rated the government’s performance as either ‘Extremely poorly’ or ‘Poor’ when it comes to protecting the health of Americans by addressing preventable medical errors and holding hospitals accountable for key quality measures.

Download the Report

About Steripath

The Steripath® Initial Specimen Diversion Device® platform offers the only all-in-one devices that are designed to meet the ENA, INS, CDC, and CLSI evidence-based best practice guidelines to reduce blood culture contamination and clinically proven to meet the CLSI and CDC’s new 1% goal for contamination.^1,2,3,4,5 To date, 20 clinical studies have been completed supporting the clinical and cost effectiveness of Steripath. All studies reported sustained contamination rates of 0-1% using Steripath, up to a 31% reduction in vancomycin days of therapy, and as much as a 12-fold decrease in false-positive central line-associated blood stream infections (CLABSIs) over extended periods of time.^6,7,8

Steripath has been adopted by hundreds of U.S. hospitals and healthcare systems to address the problem of blood culture contamination, which can lead to sepsis misdiagnosis resulting in unnecessary, prolonged, and harmful antibiotic treatment, extended length of hospital stay, false-positive CLABSIs, and wasted healthcare resources.

About Magnolia Medical Technologies

Magnolia Medical Technologies develops, manufactures, and markets innovative blood and bodily fluid collection devices to facilitate significant improvements in the accuracy, consistency, and predictability of critical laboratory tests. Magnolia Medical invented and patented the Initial Specimen Diversion Technique® (ISDT®) and Initial Specimen Diversion Device® (ISDD®) for blood culture collection and contamination prevention. The company has amassed an intellectual property portfolio, including more than 130 issued method, apparatus, and design patents with more than 50 additional patent applications pending. For more information, visit magnolia-medical.com.

Contact:

David Triana
Publicist
[email protected]

References

1. CDC. Blood Culture Contamination Prevention Actions: An Overview of Infection Control and Antibiotic Stewardship Programs Working with the Clinical Laboratory. July 2022.
2. CLSI. Principles and Procedures for Blood Cultures. 2nd Ed. CLSI Guideline M47. Clinical and Laboratory Standards Institute; 2022.
3. CDC National Email Update to Clinicians. Clinicians: Use this guide to decrease blood culture contamination rates. 2022.
4. Vanhoy MA, Horigan A, Kaiser J, et al. Emergency Nurses Association (ENA). Clinical practice guideline: prevention of blood culture contamination. 2020.
5. Gorski LA, Hadaway L, Hagle ME, et al. Infusion therapy standards of practice, 8th edition. J Infus Nurs. 2021 Jan-Feb 01;44(1S Suppl 1): S1-S224.doi: 10.1097/NAN.0000000000000396.
6. Date on file.
7. Nielsen LE, Nguyen K, Wahl CK, et al. Initial Specimen Diversion Device® reduces blood culture contamination and vancomycin use in academic medical center. J Hosp Infect. 2021;117. doi:https://doi.org/10.1016/j.jhin.2021.10.017.
8. Tompkins LS, Tien V, Madison AN. Getting to zero: impact of a device to reduce blood culture contamination and false-positive central line-associated blood stream infections. Infect Control Hosp Epidemiol. 2022;1-5. doi:10.1017/ice.2022.284.